Complement activation induces excessive T cell cytotoxicity in severe COVID-19

Profound T cell activation and induction of CD16 expressing CD4⁺, CD8⁺ TCRab⁺ and TCRgd⁺ T cells in severe COVID-19

To reveal putative immunopathogenic roles of T cells in severe COVID-19 we performed mass cytometry of whole blood samples from mild and severe COVID-19 patients during the acute and convalescent phase, patients suffering from other acute respiratory infections (Flu-like illness, FLI), patients chronically infected by human immunodeficiency virus (HIV) or hepatitis B (HBV) as well as controls (Figure 1A). We reported previously that T cell numbers were reduced in COVID-19 patients during acute infection compared to controls (Schulte-Schrepping et al., 2020). To further interrogate the T cell space, acquired T cells (CD45⁺CD3⁺CD19^-CD15^-) were pre-gated into CD4⁺ T helper cells (CD3⁺, CD8^-TCRgd^-), CD8⁺ CTLs (CD3⁺, CD8⁺TCRgd^-), and TCRgd⁺ (CD3^-, CD8^- TCRgd⁺) cells. As expected, samples from HIV patients showed an inverted CD4/CD8 ratio, whereas the proportions of all three main T cell compartments were similar between all other patient groups (mild and severe COVID-19, FLI, HBV) and controls (median levels: T helper cells 63.3-71.5%, CTLs 27.2-34.8%, TCRgd⁺ 0.9-2.9%). Unsupervised clustering analysis using 29 surface antigens and the proliferation marker Ki67 partitioned the pre-gated T helper cells, CTLs, and TCRgd⁺ T cells into 18, 15 and 14 individual cell clusters, respectively (Figure 1B-D). A significant proportion of T cells from acutely infected mild and severe COVID-19 patients were clearly separated in UMAP space from those of the other patient groups or controls (Figure 1B).

• Download figure
• Open in new tab

Figure 1. Accumulation of HLA-DR^hiCD38^hi highly activated but also CD16 expressing CD4⁺ and CD8⁺ T cells in severe COVID-19

A, Overview of the study cohort and methodological pipeline. Blood samples were collected from mild and severe COVID-19 patients during the acute and convalescent phase enrolled in Berlin (cohort 1) or Bonn (cohort 2), patients suffering from other acute respiratory infections (FLI), being chronically infected by human immunodeficiency virus (HIV) or hepatitis B (HBV) as well as controls. Mass cytometry (CyTOF) and single-cell RNA-seq combined with VDJ-seq-based T cell clonotype identification were used to determine COVID-19 as well as severity-specific alterations in the T cell compartment. The obtained results in combination with additional serum proteomics data and clinical information were used to develop hypotheses on their functional properties and mechanisms leading to their differentiation, which were tested in ex vivo cultures. Detailed sample information included in all reported assays can be found in Table S1.

B, UMAPs generated of CD4⁺ (left), CD8⁺ (middle), and TCRgd⁺ (right) T cells from mass cytometry data. Cells are colored according to donor origin (blue, age-matched controls; gray, FLI; violet, HIV; pink, HBV; yellow, mild COVID-19 acute phase; red, severe COVID-19 acute phase). For visualization purposes, each UMAP shows 28000 cells.

C, UMAPs generated of CD4⁺ (left), CD8⁺ (middle), and TCRgd⁺ (right) T cells from CyTOF data. Cells are colored according to the cell cluster origin. For visualization purposes, each UMAP shows 28000 cells.

D, Heatmap of CyTOF data (described antibody panel, cohort 1) covering CD4⁺ (left panel), CD8⁺ (middle panel) and TCRgd⁺ (right panel) T cells. Z-score standardized staining intensity of each marker (rows) per cluster (1 to 47, in columns, lower part). Clusters were grouped into metaclusters, as defined by the numbers 1 to 13 (in columns, upper part). Significance levels of differential cluster frequency for the following groups: controls (n = 9), FLI (n = 8), HIV (n = 6), HBV (n = 5), mild acute COVID-19 (n = 24) and severe acute COVID-19 (n = 29). All COVID-19 and FLI samples were collected between days 4 and 13 post-symptom onset ( = first day of sample collection per patient). The cluster abundance was tested via adjusted Dunn’s post-hoc test (Benjamini-Hochberg) for clusters with significant adjusted (Benjamini-Hochberg) Kruskal-Wallis test (adjusted p-value < 0.05). All combinations where tested, only comparisons with healthy controls are shown.

E, Box plots of CD4⁺ (7, 8, 17) and CD8⁺ (24, 25) T cell clusters determined by mass cytometry as defined in the legend (whole blood, cohort 1) generated from controls (n = 9), FLI (n = 8), HIV (n = 6), HBV (n = 5), mild acute COVID-19 (n = 16) and severe acute COVID-19 (n = 17) patient samples. KW* shows the adjusted p-value (Benjamini-Hochberg) of a Kruskal-Wallis test. The abundance of each cluster was compared between severity groups via adjusted Dunn’s post-hoc test (Benjamini-Hochberg) for clusters with KW* < 0.05. All combinations where tested, only comparisons with healthy controls are shown. (*p<0.05, **p < 0.01,***p < 0.001).

Samples of COVID-19 patients collected during the first three weeks after symptom onset independent of the severity compared to samples from patients with other infections or controls were characterized by increased proportions of CD4⁺ T helper cell cluster 7 (CD38^hiHLA-DR⁺Ki67⁺ICOS⁺), whereas the abundance of cluster 17 (CD27^-CD25⁺) was lower (Figure 1D, E). Cluster 7 T cells are characterized by high expression of activation markers such as HLA-DR, CD38, CD137, CD69, and the proliferation marker Ki67. Furthermore, the T cells in this cluster do express CXCR5, ICOS, and PD-1, resembling TFH-like cells. This increase was not seen for patients with other acute respiratory infections (FLI) or chronic viral infections (HIV or HBV). Interestingly, T helper cells in severe COVID-19 patients showed higher proportions of cluster 8 T cells (CD4⁺, highly activated Natural Killer T cell (NKT)-like), which in addition to the expression of CD38, HLA-DR, CD137, CD69, Ki67 and CXCR3, were characterized by high levels of CCR6 and CD16. Those T cells belong to the CD62L⁺CD45RO⁺ central memory metacluster, reflecting a more recent differentiation. In contrast, in patients suffering from chronic HIV or HBV infection we observed a tendency towards a higher proportion of cluster 18 (TIGIT⁺CD38⁺CD16⁺). T cells from this cluster were classified as terminally differentiated RA⁺ cells, expressed low levels of CD16, and showed no signs of recent activation such as CD137 expression

Surprisingly, this pattern of activation states was not restricted to the CD4⁺ T cell compartment, but also detectable in CD8⁺ CTLs and TCRgd⁺ T cells. Both mild and severe COVID-19 patients displayed increased proportions of cluster 24 T cells (CD8⁺CD38^hiHLA-DR⁺Ki67⁺) in comparison to the other patient groups (Figure 1D, E). Severe COVID-19 was further characterized by increased abundance of cluster 25 T cells (CD8⁺, highly activated NKT-like), also expressing high levels of CCR6 and CD16. The existence of a CD3⁺CD16⁺HLA-DR⁺ T cell population was confirmed by flow cytometry in a second cohort of COVID-19 patients (Figure S1A). In contrast, cluster 30 T cells (PD-1⁺TIGIT⁺KLRG1⁺) co-expressing CD137 and several co-inhibitory receptors (PD-1, TIGIT, LAG3) were elevated in samples from patients with other acute respiratory infections (FLI) or HIV infection. In chronic HIV and HBV infection, we observed a tendency towards a higher proportion of cluster 32 cells (LAG3⁺TIGIT⁺KLRG1⁺) containing terminally differentiated CD16 expressing T cells (data not shown).

Time-dependent analysis of the CD4⁺ and CD8⁺ T cell clusters revealed a trend to faster accumulation of the activated CD38^hiHLA-DR⁺Ki67⁺ expressing clusters 7 and 24 during the first week after SARS-CoV-2 infection in severe versus mild COVID-19 (Figure S1B, C). In contrast, the highly activated CD16 expressing NKT-like CD4⁺ and CD8⁺ T clusters appeared only during the second week of infection.

Collectively, our overall findings concerning the identification of circulating highly activated and proliferating T helper cells and CTLs after SARS-CoV-2 infection is in line with recent reports (Mathew et al., 2020; Rydyznski Moderbacher et al., 2020; Stephenson et al., 2021). However, and strikingly, we uncovered a unique activation and differentiation program in a subset of T cells across all three major T cell compartments (T helper cells, CTL and TCRgd⁺ T cells), characterized by CD16 and CCR6 expression in severe COVID-19.

Single-cell transcriptomics reveal shift towards disproportionally high cytotoxic and degranulation potential of T cells in severe COVID-19

To reveal functional information on the COVID-19- and severity-specific T cell clusters, we performed single-cell RNA-seq analysis of peripheral blood mononuclear cell (PBMC) samples as well as purified CD38 expressing T cells from acutely infected and convalescent mild and severe COVID-19, as well as FLI, HBV and controls. Cluster analysis of the whole T cell space from PBMC and CD38⁺ T cell libraries generated 15 different T cell clusters and one unspecified cell cluster (Figure 2A, B). To align the CyTOF and scRNA-seq T cell clusters, we applied a feature-based cluster annotation approach. The selected feature list contained genes for all markers analysed in CyTOF measurements plus additional genes such as T cell state-specific transcription markers (Figure 2B). T cell clusters were composed of solely CD4 expressing T cell clusters 1 to 7, mixed CD4, CD8A/B & TRGC2 expressing T cell clusters 8 and 9, mixed CD8A/B & TRGC2 expressing T cell clusters 10 to 13 as well as solely CD8 transcribing T cell clusters 14 & 15. Cluster 7, 8 and 10 were characterized by highly activated T cells with high transcription of CD38 and HLA-DR genes (Figure 2B, C). Cluster 7 T cells showed the typical features of activated TFH cells, as in addition to CD38 and HLA-DR genes, they transcribed ICOS, CD40LG, PDCD1 (PD-1) and CXCR5 (Figure 2B). Cluster 8 T cells transcribed the highest MKI67 (Ki67) levels, indicative of the highest proliferative potential (Figure 2B, C). In addition, they expressed FCGR3A, the gene encoding for CD16A, which was even more pronounced for cluster 10 T cells (Figure 2B, C). The proportion of T cells belonging to cluster 7, 8 and 10 was higher in COVID-19 patients compared to FLI or HBV patients as well as controls (Figure 2D, E). We observed other T cell clusters with FCGR3A expression (cluster 9, 11, 12, 13). Only cluster 9 T cells transcribed SELL (CD62L) and displayed a central memory phenotype, whereas cluster 11, 12 and 13 T cells displayed a more advanced differentiation profile. Overall, cluster 7 contains TFH-like cells similar to the CyTOF cluster 7, whereas cluster 8, 9 and 10 most likely contain a mixture of highly activated and CD16⁺ NKT-like cells with similarities to the CyTOF clusters 8, 24 and 25. Next, we performed a Gene Ontology (GO) enrichment analysis across clusters 7, 8, 9 and 10, comparing mild and severe COVID-19 T cells (Figure 2F). Interestingly, whereas T cells from mild COVID-19 patients showed an enrichment for cellular responses to type I interferon and antiviral defense, we observed a very specific enrichment of genes involved in degranulation in severe COVID-19 T cells. This selective enrichment was validated by a Gene Set Enrichment Analysis (GSEA) for genes belonging to the GO terms ‘response to type I interferon’ and ‘defense response to virus’, which were enriched in mild, and for genes belonging to a cytotoxicity signature, which were enriched in severe COVID-19 T cells (Figure 2G). Indeed, several genes known to promote degranulation (LAMP1, STX11) or exerting cytotoxic potential (PRF1, GZMB, GZMH, GZMK) displayed a tendency towards higher expression in severe COVID-19 across clusters 7, 8, 9 & 10 T cells (Figure 2H+S2B) or the whole T cell space (Figure S2C). Importantly, we validated these findings in scRNA-seq data from our second cohort (Figure S3). Applying the same feature selection-based annotation approach to the second cohort resulted in identification of COVID-19-specific T cell clusters, which consistently aligned to the ones from the first cohort (Figure S3A-D). Cluster 6 and 7 contained CD4⁺ T cells transcribing ICOS, CD40LG, PDCD1 and CXCR5 and thus resembled cluster 7 T cells from cohort 1, although the expression level of CD38 and HLA-DR genes seemed to be lower. Clusters 10 & 13 from the second cohort resembled cluster 10 & 8 in cohort 1, respectively. Furthermore, GSEA similarly showed increased expression of genes mediating cytotoxicity in severe COVID-19 T cells across these clusters (Figure S3E, F).

• Download figure
• Open in new tab

Figure 2. Single-cell transcriptomics of T cells during acute mild and severe COVID-19

A, UMAP of T cell clusters retrieved from merging scRNA-seq libraries of 5’-libraries of PBMC samples and 5’-libraries of enriched CD38⁺ CD4⁺ and CD8⁺ T cells collected from controls (n = 3), FLI (n = 5), HBV (n = 4), mild COVID-19 (n = 9) and severe COVID-19 (n = 12) patients.

B, Heatmap of T cell cluster retrieved from merging scRNA-seq libraries of 5’-libraries of PBMC samples and 5’-libraries of enriched CD38⁺ CD4⁺ and CD8⁺ T cells collected from controls (n = 3), FLI (n = 5), HBV (n = 4), mild COVID-19 (n = 9) and severe COVID-19 (n = 12) patients.

C, UMAPs of T cell clusters as shown in A with superimposed CD4, CD8A, FCGR3A, MKI67, CD38 and HLA-DRA expression.

D, UMAP of T cell clusters as shown in A with cells coloured according to disease group origin: blue, age-matched controls (n = 3); gray, FLI (n = 5); pink, HBV (n = 4); yellow, mild COVID-19 acute phase (n = 6); red, severe COVID-19 acute phase (n = 7). For visualization purposes, cells were downsampled to 5000 cells per disease group.

E, Box plots of a selection of scRNA-seq T cell clusters whose abundances is either higher in both mild and severe COVID-19 (clusters 7 & 8) or which display FCGR3A expression and show a tendency to be increased in severe COVID-19 (clusters 9 & 10) generated from controls (n = 3), FLI (n = 5), HBV (n = 4), mild COVID-19 acute phase (n = 6) and severe COVID-19 acute phase (n = 7) patient samples. KW* shows the adjusted p-value (Benjamini-Hochberg) of a Kruskal-Wallis test.

F. Bar plot indicating the negative log2-transformed adjusted p-value (Benjamini-Hochberg) of the 20 most significant enriched pathways that are (top) upregulated in mild COVID-19 acute phase, compared to severe COVID-19 acute phase, (bottom) upregulated in severe COVID-19 acute phase, compared to mild COVID-19 acute phase. Pseudobulk gene expression was calculated per sample among scRNA-seq T cell clusters 7, 8, 9 & 10.

G, Enrichment plots from GSEA performed on the ranked gene list of the comparison severe vs. mild COVID-19. The graph shows the mapping of the signature genes on the ranked gene list. The curve corresponds to the running sum of the weighted enrichment score (ES). The ranked gene list was calculated from the normalized pseudobulk expression data of severe and mild COVID-19 acute phase among scRNA-seq T cell clusters 7, 8, 9 & 10.

H, Box plots of the average log2-transformed expression among T cell clusters 7, 8, 9 & 10 from mild (n = 6) and severe (n = 7) COVID-19 acute samples, for three genes included in the cytotoxicity signature (LAMP1, GZMB and PRF1).

Thus, scRNA-seq analysis of samples from two cohorts strongly supported our CyTOF finding of a subset of activated CD16 expressing T cells across the major T cell compartments in severe COVID-19 and identified an increase in cytotoxicity-associated transcriptional programs.

CD8⁺ T cells from severe COVID-19 patients display CD16-mediated degranulation potential leading to chemokine production by co-cultured primary lung microvascular endothelial cells

CyTOF and scRNA-seq analyses identified two main T cell activation features i) formation of highly activated, proliferating TFH-like CD4⁺ cells and CXCR3 expressing CTLs independent of disease severity, and ii) activated CD16 expressing T cells specific for severe COVID-19. Since TFH cells are known to promote B cell help (Crotty, 2014) and since we observed a trend for faster formation of activated TFH-like cells in severe COVID-19 patient samples, we tested whether SARS-CoV-2-specific antibody responses were more pronounced in those patients. Indeed, serum concentrations of SARS-CoV-2-specific IgA, but particular IgG levels were higher in severe COVID-19 (Figure 3A). These findings are in line with previous reports stating highest levels of both IgA and IgG in severely ill COVID-19 patients (Garcia-Beltran et al., 2021). Furthermore, maximal antibody levels determined during the second week post-symptom onset correlated positively with the cell proportions of the TFH-like CyTOF cluster 7 (Figure 3B), whereas the CD16⁺CD4⁺ T cell cluster 8 did not correlate with antibody levels (IgA: R²= 0.11, p= 0.19; IgG: R²= 0.18, p= 0.08; data not shown).

• Download figure
• Open in new tab

Figure 3. Increased degranulation and cytotoxic potential of T cells from severe COVID-19

A, Box and whisker (5–95 percentile) plots of SARS-CoV-2-specific IgG and IgA antibody levels detected as described in material and methods in serum samples from mild (n = 15) and severe (n = 17) COVID-19 patients collected between day 10 and 14 post symptom onset. Wilcoxon test **p < 0.01.

B, Linear regression analysis of circulating TFH cell proportions (CyTOF T cell cluster 7) determined in whole blood samples collected from mild (n = 8) and severe (n = 11) COVID-19 from cohort 1 during day 5 and 14 post-symptom onset and SARS-CoV-2-specific IgG and IgA serum levels.

C, Exemplary dot plots revealing the degranulation capacity of CD8⁺ T cells from PBMCs of a mild and severe COVID-19 patient as well as a non-infected control proband. Degranulation capacity is defined by the increase of cell surface CD107a expression upon stimulation with anti-CD16 antibody-coated or isotype-coated beads.

D, Box and whisker (5–95 percentile) plots summarising the Granzyme B expression (unstimulated) and degranulation capacity of CD8⁺ T cells from PBMCs of mild (n = 9) and severe (n = 10) COVID-19 patients as well as non-infected controls (n = 6) defined by their increase of cell surface CD107a expression upon stimulation with anti-CD16 antibody-coated or isotype-coated beads. Wilcoxon test *p<0.05, **p < 0.01.

E, Box and whisker (5–95 percentile) plots summarising the normalised release of CXCL8 and CCL2 by primary lung endothelial cells co-cultured with CD8⁺ T cells enriched from PBMCs of mild (n = 6) and severe (n = 5) COVID-19 patients as well as non-infected controls (n = 5) upon stimulation with ConA or anti-CD16 antibody-coated beads measured by multiplex assay. Wilcoxon test *p<0.05.

F, Endothelial cell resistance upon stimulation with ConA alone (n = 5) or additional co-culture with CD8⁺ T cells enriched from PBMCs of mild (n = 6) and severe (n = 5) COVID-19 patients as well as non-infected controls (n = 5). Kruskal-Wallis test *p<0.05.

G, UMAP of T cells generated from the BAL sample dataset of Wauters et al. (Wauters et al., 2021), including COVID-19 (n = 22) and control pneumonia (n = 13) samples.

H, UMAPs of T cell clusters as shown in G with superimposed CD38, HLA-DRA and FCGR3A expression.

I, Confusion matrix showing the percentage of the relative contribution of each group in each cluster. Each group was normalized to the same total number of cells to avoid biases derived from different cell numbers.

J, Dot plot of the expression of the genes included in the “Cytotoxicity” signature as applied in the analyses of PBMC samples (Figure 2, S3) and FCGR3A in the T cell clusters as shown in G. The dots are colored by the scaled gene expression across the clusters and the size is proportional to the ratio of cells expressing the specific gene.

Next, we investigated the functional properties related to the CD16 expressing CD4⁺ and CD8⁺ T cell clusters. Since CD16 is known to mediate antibody-mediated degranulation of NK cells (Moretta et al., 2008), we tested whether T cells from severe COVID-19 patients display enhanced CD16-dependent degranulation potential. As a surrogate for immune complex-mediated T cell stimulation, we assessed intracellular Granzyme B and cell surface CD107a in PBMCs from mild or severe COVID-19 patients as well as controls after a 6-hour incubation with anti-CD16 antibody or isotype antibody--coated beads (Figure 3C, D). As predicted by scRNA-seq, samples from severe COVID-19 patients contained significantly more Granzyme B expressing CD8⁺ T cells compared to controls. Furthermore, stimulation with anti-CD16 but not isotype-coated beads elicited stronger degranulation (CD107a surface expression) of severe COVID-19 CD8⁺ T cells compared to T cells from mild COVID-19 (Figure 3D). In contrast, control T cells had very low degranulation potential.

One of the most likely implications of CD16 engagement in severe COVID-19 is enhanced T cell degranulation during interaction with endothelial cells (Bagnato and Harari, 2015; Degauque et al., 2021). Indeed, based on findings from autopsies in severe COVID-19, T cell infiltration along with endothelial cell injury known as lymphocytic endotheliitis has been observed (Miyazawa, 2020; Varga et al., 2020). One could envision that immune complexes made of virus particles and antibodies elicit degranulation of CD16 expressing T cells which contributes to endothelial injury. To test this hypothesis, we co-cultured primary lung microvascular endothelial cells with enriched non-naive (CD45RA^+/-, CCR7^-) CD8⁺ T cells from mild or severe COVID-19 as well as control T cells in the presence of anti-CD16 antibody. Subsequently, release of inflammatory mediators was analysed (Figure 3E). Anti-CD16-triggered severe COVID-19 T cells elicited enhanced CXCL8 (IL-8) and CCL2 (MCP-1) release by co-cultured endothelial cells. Importantly, chemokines were produced by endothelial cells as we did not observe chemokine release by anti-CD16-triggered T cells cultured alone (data not shown). We also analysed whether non-naive CD8⁺ T cells from mild and severe COVID-19 have a greater potential to amplify Concanavalin A (ConA)-mediated endothelial cell activation and loss of endothelial cell barrier function compared to control T cells. T cells from both mild and severe COVID-19 patients showed a higher potential to reduce transendothelial electrical resistance compared to control T cells, but this effect was only significant for T cells from severe COVID-19 (Figure 3F).

Next, we investigated whether CD16 expressing T cells are found locally in COVID-19. To study this we made use of a published scRNA-seq data set of bronchoalveolar lavage (BAL) samples from COVID-19 patients and patients with non-COVID-19 pneumonia (Wauters et al., 2021). Cluster analysis of the T cell space generated 11 clusters (Figure 3G). Whereas most T cell clusters contained CD38 and HLA-DRA transcribing cells, FCGR3A expression was more or less confined to cluster 3, 6, 10 and 11 (Figure 3H). The abundance of cluster 3, 10 and 11 was higher in COVID-19 samples (Figure 3I). Importantly, cluster 10, showing the strongest enrichment in COVID-19 samples, was characterized by the highest FCGR3A expression. In addition, T cells belonging to this cluster transcribed nearly all genes of the cytotoxicity signature including LAMP1 at the highest level (Figure 3J).

These findings support our hypothesis of a COVID-19-specific generation and local accumulation of CD16⁺, highly cytotoxic T cells, which can induce activation and injury of lung endothelial cells. T cell-induced release of chemoattractants CXCL8 and CCL2 can contribute to increased infiltration of neutrophils and monocytes in COVID-19 pneumonia.

FCGR3A expressing T cell clones induced during acute severe COVID-19 persist and maintain their increased cytotoxic potential

Knowing that CD16 expressing T cells from severe COVID-19 patients display enhanced cytotoxic properties potentially contributing to organ damage, we analysed whether they persist (in circulation) after clearance of the acute infection. To do so, we obtained VDJ sequence information in addition to the gene expression data of T cells from acute and convalescent samples of mild and severe COVID-19 as well as FLI, HBV and controls, allowing us to study the fate of early expanded T cell clones during convalescence at months 3 to 4 post-symptom onset (Figure 4 A-E). First, we analysed whether the individual COVID-19 T cell clusters differ in their clonal enrichment. Interestingly, the FCGR3A expressing SARS-CoV-2-specific scRNA-seq T cell clusters 8 and 10 (introduced in Figure 2) showed a high level of clonal enrichment during acute COVID-19 infection, which was rather low for cluster 7, the cluster containing solely CD4⁺ TFH-like cells (Figure 4A). Consequently, only clones belonging to cluster 8, 9 and 10, composed of mixed CD4/CD8A or CD8A/TCRgd T cell clusters, displayed a high degree of persistence with up to 50% of the TCR clones being recovered in convalescent samples (Figure 4B). Furthermore, clones expanded in the highly proliferating cluster 8 showed a higher persistence in severe COVID-19 patients (Figure 4B). Following the clone-specific VDJ sequences also allowed us to track in which cluster these clones accumulated during convalescence, in other words, whether they either kept or changed their molecular phenotype as assessed by scRNA-seq (Figure 4C, D). While the T cells expanded during the acute infection and belonging to the SARS-CoV-2-specific clusters 7, 8 and 10 dropped dramatically during convalescence (Figure 4D) the respective T cell clones from clusters 8 and 10 as determined by TCR clonal fate analysis evolved into T cells mainly identified in clusters 11 and 12 which were still characterized by FCGR3A expression (Figure 4C, D). We therefore tested whether the convalescent clusters also maintained their enhanced cytotoxic potential (Figure 4E). Indeed, GSEA revealed increased expression of genes from the cytotoxicity signature among clusters 6, 11 and 12 T cells of COVID-19 patients versus controls, with an evident difference even when comparing severe versus mild COVID-19 (Figure 4E).

• Download figure
• Open in new tab

Figure 4. Time-dependent evolution and phenotype of T cell clones expanded during acute COVID-19

A, Percentage of expanded and non-expanded T cell clones in clusters 7, 8, 9 & 10. A cell that has the same clonotype in more than 1 per 1000 cells over all T cells per patient (controls, n = 3; FLI, n = 5; HBV, n = 4; mild COVID-19 acute phase, n = 6; severe COVID-19 acute phase, n = 7) was considered as an expanded clone.

B., Percentage of T cell clones from clusters 7,8,9 & 10 acute phase found in convalescent samples (mild COVID-19, n = 3; severe COVID-19, n = 5)

C, Flow diagram representing the cluster trajectory of clones present in acute (left) and convalescent (right) COVID-19 samples (mild COVID-19, n = 3; severe COVID-19, n = 5).

D, Percentage of cells in selected clusters for each COVID-19 sample (mild COVID-19, n = 3; severe COVID-19, n = 5).

E, Enrichment plots from GSEA performed on the ranked gene list of the comparison (left) control vs. convalescent COVID-19 (mild and severe), and (right) severe vs. mild convalescent COVID-19. The graph shows the mapping of the signature genes on the ranked gene list. The curve corresponds to the running sum of the weighted enrichment score (ES). The ranked gene list was calculated from the normalized pseudobulk expression data per sample among scRNA-seq T cell clusters 6,11 & 12.

F, Box plots summarising the percentage of cells belonging to the indicated CD4⁺ (7, 8 & 18) and CD8⁺ (24, 25, 29 & 32) CyTOF cluster in samples from mild and severe patients during the acute (mild n = 20, severe n = 24) and convalescent phase (mild n = 13, severe n = 12). KW* shows the adjusted p-value (Benjamini-Hochberg) of a Kruskal-Wallis test. The abundance of each cluster was compared between severity groups via adjusted Dunn’s post-hoc test (Benjamini-Hochberg) for clusters with KW* < 0.05. All combinations were tested, only comparisons between the acute and convalescent phase within each COVID-19 severity group are shown (*p<0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

Using the VDJ sequence information allowed us also to define whether the activated FCGR3A⁺ T cell clusters are mainly composed of NKT cells known to show innate immune cell functions (Krovi and Gapin, 2018). With the the vast majority of iNKT cells expressing an identical TCRα chain (TRAV10-TRAJ18) paired to a restricted set of TCRβ chains (TRBV25), we determined the proportion of TRAV10-TRAJ18-TRBV25 pairing T cell clones across all T cell clusters. The median proportion of T cells expressing the TCR alpha-beta pair and thus resembling iNKT cells was 4.7%. Apart from cluster 10, we did not observe a major iNKT cell enrichment in the described COVID-19 T cell clusters (C7 = 3.73%, C8 = 6.52%, C9 = 2.12%, C10 = 13.46%). However, this shows that although the proportion of TRAV10-TRAJ18-TRBV25 pairing T cell clones was higher in cluster 10, most clones expressed other alpha and beta chain genes and thus do not resemble iNKT cells.

Furthermore, we performed CyTOF analysis of samples during COVID-19 convalescence (Figure 4F). Similar to the scRNAseq findings, we observed alterations in T cell cluster abundances during convalescence. For CD8⁺ T cells, we observed a strong increase in T cell proportions for cluster 29, which belongs to the effector memory meta cluster and is characterized by PD-1, TIGIT as well as CD137 expression. In line with the scRNA-seq data for which we detected a decline of the acutely expanded T cell clusters, proportions of highly activated (clusters 7 and 24) and CD16 expressing NKT-like (clusters 8 and 25) CD4⁺ and CD8⁺ clusters decreased in the convalescent phase. However, CD16 expressing T cells did not disappear. In the CD4⁺ T cell compartment, we observed an increase in the CD16 expressing late differentiated TEMRA cluster 18, which was more pronounced in severe COVID-19 patients. Similarly, proportions of T cells belonging to the CD8⁺ CD16 expressing TEMRA cluster 32 were higher in the convalescent phase.

Thus, in summary, CD16 expressing CD8⁺ T cells in particular of severe COVID-19 patients persist during convalescence, adopt a more differentiated, CD62L-negative phenotype but maintain their high cytotoxic potential.

Age-dependent reinforcement of C3a generation promotes differentiation of CD16 expressing highly cytotoxic T cells

We next elucidated the mechanisms leading to accumulation of activated CD16 expressing highly cytotoxic T cells in severe COVID-19.

Since mortality and severe morbidity in COVID-19 disproportionately affects those of advanced age (Nanda et al., 2020), we investigated whether formation of CD16 expressing T cells is associated with increased age. We utilized flow cytometry data available from our recently published control cohorts, in which we assessed age- and sex-dependent changes of peripheral blood immune cell populations in healthy individuals (Kverneland et al., 2016). Also blood samples from controls contain some CD16 expressing CD4⁺ and CD8⁺ T cells, yet at very low proportions (Figure 5A), which is in line with the here-reported findings (Figure 1+S1). Especially for CD8⁺ T cells, we detected significantly higher proportions of CD16 expressing cells in samples from older individuals, supporting our hypothesis of an age-dependent increase.

• Download figure
• Open in new tab

Figure 5. Age-dependent enforcement of C3a generation promotes differentiation of CD16 expressing highly cytotoxic T cells

A, Box and whisker (5–95 percentile) plots showing the proportions of CD16 expressing CD8⁺ and CD4⁺ T cells in whole blood samples of controls (n = 95) according to their age (<50 n = 59, >50 n = 36). Wilcoxon test *p<0.05.

B, Linear regression analysis of age and plasma CFD levels determined by mass spectrometry in samples from the Generation Scotland study (Messner et al., 2020).

C, Box and whisker (5–95 percentile) plots summarising the CFD plasma levels determined by mass spectrometry in samples collected from mild (week 2, n = 5; week 3, n = 7) and severe (week 2, n = 7; week 3, n = 17) COVID-19 patients during week two or three post-symptom onset. Wilcoxon test *p<0.05. Longitudinal changes of plasma C3a and C5a concentrations in samples from mild (n = 12) and severe (n = 17) COVID-19 and FLI (n = 8). Kruskal-Wallis and Dunn’s multiple comparison test **p < 0.01, ***p < 0.001, ****p < 0.0001.

D, Scatter plots showing the differences in C3a binding capacity of non-naive CD4⁺ and CD8⁺ T cells enriched from PBMCs of mild (n = 3) or severe (n = 5) COVID-19 patients or controls (n = 6) determined by flow cytometry. Wilcoxon test *p<0.05.

E, Linear regression analysis of the proportions of T cells belonging to CyTOF cluster 8 or 25 and plasma C3a levels in acute COVID-19 samples (n = 26).

F, Box and whisker (5–95 percentile) plots showing the percentage of CD16 expressing CD4⁺ and CD8⁺ T cells upon one-week stimulation of enriched CD3⁺ T cells from controls with anti-CD3/ CD28 antibodies and IL-2 in medium containing serum from mild (n = 19), severe (n = 19) COVID-19 patients or AB serum in the presence or absence of recombinant C3a (n = 8). Wilcoxon test *p<0.05, **p<0.01.

G, Scatter plots showing the cell surface CD107a expression level of CD4⁺ and CD8⁺ T cells upon one-week stimulation of enriched CD3⁺ T cells from controls with anti-CD3/CD28 antibodies and IL-2 in medium containing serum from mild (n = 6), severe (n = 6) COVID-19 patients or AB serum (n = 6). Friedmann and Dunn’s multiple comparison test *p<0.05.

H, Scatter plots revealing the changes in the proportions of CD16 expressing CD4⁺ and CD8⁺ T cells upon one-week stimulation of enriched CD3⁺ T cells from controls with anti-CD3/CD28 antibodies and IL-2 in medium containing serum from mild or severe COVID-19 patients upon neutralisation of C3a (n = 6). Wilcoxon test *p<0.05.

Next, we sought to identify signals eliciting CD16 expression on T cells. A key feature of severe COVID-19 is increased complement generation and activation (Carvelli et al., 2020; Ma et al., 2021; Sinkovits et al., 2021). The complement system is an integral part of the innate immune defense involved in opsonization, chemotaxis and pathogen lysis (Noris and Remuzzi, 2013). Apart from these well-known complement activities, it has become clear that its effector functions also extend to an instruction of the adaptive immune system (Lubbers et al., 2017). In particular, complement enhances T cell activation as T cells are known to express receptors for C3a and C3b and react to triggering these receptors (Arbore et al., 2018; Hess and Kemper, 2016; West et al., 2018).

To corroborate a potential link between aging and an increase in complement activity, we analyzed the correlation of the complement component complement factor D (CFD) with age in the generation Scotland study (Figure 5B, (Messner et al., 2020)), which revealed a clear age-dependent increase of CFD. We then extended these findings to COVID-19 patients included in our CyTOF analysis and showed that particularly severe COVID-19 at early time points were characterized by significantly elevated CFD plasma concentrations (Figure 5C, left panel).

CFD is a serine protease that catalyses an important step in the formation of the active C3 convertase of the alternative pathway also known as spontaneous “tick-over” mechanism of complement activation (Noris and Remuzzi, 2013). Thus, higher CFD expression levels result in higher levels of C3a. Indeed, C3a plasma levels detected in severe COVID-19 patients during the first three weeks after symptom onset exceeded C3a levels detected in the plasma of mild COVID-19, or other acute respiratory infections (Figure 5C, middle panel). C5a levels peaked in weak three post onset of symptoms but did not reach significance (Figure 5C, right panel). We next assessed whether T cells show elevated binding potential for C3a in COVID-19. Both, CD4⁺ and CD8⁺ T cells from COVID-19 patients regardless of disease severity displayed higher C3a binding potential than cells from controls (Figure 5D). Finally, plasma C3a levels in COVID-19 patients measured at week 2 post-symptom onset correlated with proportions of COVID-19-specific activated CD16 expressing CD4⁺ and CD8⁺ CyTOF clusters (cluster 8+25) (Figure 5E).

To test whether there is a direct link between plasma / serum protein components and differentiation of activated CD16 expressing T cells, we stimulated enriched CD3⁺ cells from healthy unexposed controls with plate-bound anti-CD3/CD28 antibodies in the presence of recombinant IL-2 and serum from mild or severe COVID-19 patients or control AB serum. As shown in figure 5F, addition of serum from severe COVID-19 patients resulted in a 10- and 20-fold increase of CD16 expressing CD4⁺ and CD8⁺ T cells, respectively, which was significantly higher compared to the increase observed when adding serum from mild COVID-19 patients. Furthermore, addition of recombinant C3a to cells stimulated in the presence of control AB serum enhanced formation of CD16 expressing CD4⁺ and CD8⁺ T cells (Figure 5F). The in vitro-generated T cells did not only phenotypically resemble the ones identified in our CyTOF analyses but also shared functional properties as T cells stimulated in the presence of serum from severe COVID-19 patients displayed a higher degranulation potential (Figure 5G).

Finally, we tested whether C3a is responsible for the altered T cell differentiation potential of serum samples from severe COVID-19 patients. Indeed, neutralisation of C3a resulted in reduction of CD16⁺ T cells in most T cell differentiation cultures (Figure 5H).

In summary, complement split products such as C3a produced at high levels in severe COVID-19 generate an inflammatory milieu which promotes differentiation of CD16 expressing, highly cytotoxic T cells.

Proportion of activated CD16⁺ T cells and complement protein expression determines outcome of COVID-19

Revealing a connection between the complement system and differentiation of activated CD16⁺ T cells in severe COVID-19, we investigated their relation to patient outcome in COVID-19.

We first analysed whether proportions of activated CD16 expressing T cells were higher in severe COVID-19 patients who died during follow-up in both study cohorts. In order to define an objective way to select the sum of all activated CD16⁺ TCRab⁺ clusters of our CyTOF data set (cohort 1), we computed an activation value for each cluster in the TCRab⁺ space, defined as the mean of the average z-scored expression of activation markers (CD25, HLA-DR, CD38, CD137, CD69, and Ki67). Then, clusters with an activation value higher than the average, and with an average z-scored CD16 expression higher than 1, were considered activated CD16⁺ TCRab⁺ T cell clusters (CyTOF cluster: C8 = CD4⁺ central memory highly activated NKT-like, C12 = CD4⁺ effector memory highly activated NKT-like, C25 = CD8⁺ central memory highly activated NKT-like). We observed a trend to higher percentages of activated CD16⁺ TCRab⁺ cells among all CD4⁺ and CD8⁺ T cells in samples from severe COVID-19 patients who deceased(non-survivor) compared to those who survived (survivor) (Figure 6A, second left panel). Furthermore, proportions of CD3⁺CD16⁺HLA-DR⁺ T cells as measured in cohort 2 by multicolor flow cytometry also showed a trend to be higher in severe COVID-19 patients who deceased during follow-up (Figure 6A, middle panel).

• Download figure
• Open in new tab

Figure 6. Proportion of activated CD16⁺ T cells and complement protein expression determines outcome in COVID-19

A, Subgroup analysis of activated CD16⁺ T cell proportions according to survival of severe COVID-19 patients. Left panel, cartoon summarizing the data analysis, data obtained from samples of severe COVID-19 patients (WHO 5-7) were divided according to patient survival. Second left panel, box plots of proportions of activated CD16⁺TCRab⁺ T cells across all T cell clusters determined by mass cytometry (whole blood, CyTOF cohort 1) generated from surviving (n = 11) and non-surviving (n = 5) week 2 or week 3+ severe acute COVID-19 patient samples. The sample with the highest WBC was selected per patient in case of repeated measurements. Middle panel, box plots of CD16⁺HLA-DR⁺ CD3⁺ T cells determined by flow cytometry (cohort 2) of week 2 or week 3+ samples from surviving (n = 8) or non-surviving (n = 6) severe COVID-19 patients collected during the acute infection. The sample with the highest WBC was selected per patient in case of repeated measurements. Right panel, proportions of activated FCGR3A⁺ T cells (from scRNAseq clusters 8, 10 & 13, cohort 2) within the whole TCRab⁺ T cell space. The proportions of T cells between samples from surviving and non-surviving severe COVID-19 patients were compared using the Wilcoxon test.

B, Box plots showing plasma expression levels of complement proteins upstream of C3a generation determined by mass spectrometry (proteomics) as described in material and methods which are significantly different between samples from mild (n = 44) and severe (n = 66) COVID-19 patients of cohort 1. The complement protein expression levels between samples from mild and severe COVID-19 patients were compared using the Wilcoxon followed by post-hoc Benjamini Hochberg test.

C, Subgroup analysis of plasma complement protein expression levels upstream of C3a generation according to worsening of WHO scale. Upper panel, cartoon summarizing the data analysis, data obtained from samples of mild and severe COVID-19 samples were divided according to the subsequent WHO scale development (delta WHO). Lower panel, box plots showing plasma expression levels of complement proteins which are significantly different between samples from patients with non-worsening WHO scale (n = 91) and worsening WHO scale (n = 19) of mild or severe COVID-19 patients from cohort 1. The complement protein expression levels between the groups were compared using the Wilcoxon followed by post-hoc Benjamini Hochberg test.

D, Subgroup analysis of plasma complement expression levels according to survival of severe COVID-19 patients. Box plots showing plasma expression levels of complement proteins upstream of C3a generation which are significantly different between samples from severe COVID-19 patients (WHO 5-7) who were divided according to patient survival (survivors, n = 48; non-survivors, n = 18). The complement protein expression levels between the groups were compared using the Wilcoxon followed by post-hoc Benjamini Hochberg test.

In addition, we tested whether the proportion of activated FCGR3A expressing scRNAseq clusters correlates with survival of severe COVID-19 patients. We applied a similar two-step strategy to select all activated FCGR3A⁺ TCRab⁺ clusters as described for the CyTOF data. All T cell clusters which showed an above mean activation value, calculated as mean z-score of activation markers as defined in Figure S3B, and clusters which showed FCGR3A transcription were selected (Figure S3B, cluster 10, 13 and 18). Again, the percentage of T cells belonging to activated FCGR3A⁺ T cell clusters showed a trend to be higher in severe COVID-19 patients who deceased (Figure 6A, right panel). Together, this difference was significant, when analysed across methods (CyTOF, MCFC, scRNAseq) and cohorts (p=0.011, Fisher’s method, df=6)

Next, we tested in a larger cohort whether expression of complement proteins upstream of C3a generation (C1QA, C1QB, C1QC, C1R, C1S, C2, C3, C4, C4A, C4B, C4BPA. C4BPB, CFB, CFD, CFH, CFI, MASP1, MASP2, MBL2) is associated with patient disease course and outcome. As shown in figure 6B, expression levels of positive regulators of the classical and alternative pathway such as C1QA, C1QB, C1QC, C1R, and CFD were higher in plasma samples of severe compared to mild COVID-19 patients (Figure 6B). We also analysed the complement protein expression level according to subsequent worsening of disease severity, i.e., increase of WHO scale. This also revealed higher expression of C1R and CFD in samples from patients who showed an increase in WHO scale during follow-up, whereas the expression of CFI, which inhibits the classical and lectin-dependent complement pathway was lower in samples from patients with subsequent disease progression (Figure 6C). Finally, amounts of C1QA, C1QB, C1QC and CFD were not only higher in severe COVID-19 but also determined their survival (Figure 6D).

Altogether these data further support the pathological role of complement-mediated formation of activated CD16⁺ T cells during severe COVID-19.

Limitations of the study and future directions

The relatively low number of matched acute and convalescent samples for scRNA-seq analysis limited the comparisons regarding differences in clonal persistence and phenotype between mild and severe COVID-19 patients. Thus, larger studies are needed to confirm the observed increased persistence of late differentiated, CD16 expressing, highly cytotoxic CTLs upon an acute severe disease course. Also, the limited number of convalescent samples did not allow us to perform correlations with patient recovery. Here, our major focus was to reveal immunopathogenic functions of severity-associated T cell populations during acute COVID-19 and to identify driving signals.

In this context, it will be of great interest to see whether application of the C3 inhibitor AMY-101 in COVID-19 patients with ARDS will ameliorate differentiation of CD16 expressing, cytotoxic T cells and thus endothelial cell injury and lymphocytic endotheliitis.

Taken together, particularly severe COVID-19 leads to an elevation of activated CD16⁺ T cells that link the elevated complement cascade via TCR-independent cytotoxic T cell functionality to endothelial damage and patient survival, thereby establishing a novel immunopathological link between the innate immune system, the adaptive immune compartment, and endothelial injury, which might constitute an important molecular axis explaining the vast spectrum of organ damage observed in COVID-19.

Resource availability

Blood processing and data analysis for multi-color flow cytometry

Isolation of blood cells for scRNA-seq (cohort 1)

Human peripheral blood mononuclear cells (PBMCs) were isolated from heparinized whole blood by density gradient centrifugation over Pancoll (density: 1,077g /ml, PAN-Biotech, Germany). Subsequently the cells were counted, frozen and stored in liquid nitrogen. On the day of the experiment the frozen PBMCs were thawed in pre-warmed thawing medium (RPMI 1640, Gibco; 2% FCS, Sigma; 0,01% Pierce Universal Nuclease, Thermo Fisher, USA).

10x Genomics Chromium single-cell RNA-seq (cohort 1)

Approximately 2-3 x10⁵ PBMCs were resuspended in staining buffer (DPBS, Gibco; 0,5% BSA, Miltenyi Biotec, Germany; 2 mM EDTA, Gibco, Thermo Fisher Scientific, USA) and hashtagged with 0.5 µg Total-Seq-C™ Hashtag antibodies for 30 min at 4°C. After the incubation PBMCs were washed three times. Subsequently PBMC were counted and up to four different samples were pooled equally. The PBMCs were washed three times, resuspended in DPBS, filtered through a 40 µm mesh (Flowmi™ Cell Strainer, Merck, Germany) and counted using the C-Chip hemocytometer (NanoEntek, South Korea). The cell suspension was super-loaded with 40000 - 50,000 cells per lane, in the Chromium™ Controller for partitioning single-cells into nanoliter-scale Gel Bead-In-Emulsions (GEMs).

Remaining PBMCs were subjected to flow-cytometric sorting based on DAPI, CD3 (clone UCHT1), CD4 (clone RPA-T4), CD8 (RPA-T8) and CD38 (clone HB7) antibody staining and simultaneously hashtagged as described above. Live (DAPI-) CD3⁺CD4⁺CD38⁺ as well as CD3⁺CD8⁺CD38⁺ cells were sorted using the FACS Aria II (BD Biosciences, USA). Afterwards CD4⁺CD38⁺ and CD8⁺ CD38⁺ T cells from each donor were pooled equally and CD38⁺ T cells from up to four samples were pooled to equal proportions. The resulting cell pool was resuspended in DPBS, filtered through a 40 µm mesh (Flowmi™ Cell Strainer, Merck, Germany) and counted using the C-Chip hemocytometer (NanoEntek, South Korea). The cell suspension was super-loaded with 40,000 - 50,000 cells per lane, in the Chromium™ Controller for partitioning single-cells into nanoliter-scale Gel Bead-In-Emulsions (GEMs).

The Chromium Next GEM Single Cell 5′ Kit v1.1 was used for reverse transcription, cDNA amplification and library construction of the gene expression libraries (10x Genomics, USA). For additional VDJ and hashtag libraries the Chromium Single Cell V(D)J Enrichment Kit, Human T Cell (10x Genomics, USA) and the Chromium Single Cell 5’ Feature Barcode Library Kit (10x Genomics, USA) were used respectively. All libraries were prepared following the detailed protocols provided by 10x Genomics, quantified by Qubit Flex Fluorometer (Thermo Fisher, USA) and quality was checked using 2100 Bioanalyzer with High Sensitivity DNA kit (Agilent, USA). Sequencing was performed in paired-end mode with a S1 and S2 flow cell using NovaSeq 6000 sequencer (Illumina, USA).

BD Rhapsody single-cell RNA-seq (cohort 2)

For the analysis of the T lymphocytes compartment of COVID-19 patients, the PBMC dataset from Schulte-Schrepping et al. (Schulte-Schrepping et al., 2020) was used. The dataset was provided as a Seurat object of the PBMCs samples from the original study including all pre-processing and filtering criteria as described in the original manuscript. The data can be downloaded from FASTGenomics [https://beta.fastgenomics.org/p/schulte-schrepping_covid19] or directly explored using the web platform.

Data pre-processing of 10x Genomics Chromium scRNA-seq data (cohort 1)

The Cell Ranger Software Suite (Version 5.0.0) was used to process raw sequencing data, using the cellranger multi workflow and the GRCh38 references for gene expression and VDJ data and totalSeq antibody barcode sequences for feature barcoding data. Multiplexed samples from multiple donors were demultiplexed by detecting SNPs using CellSNP-lite (Huang and Huang, 2021).

ScRNA-seq data analysis of 10x Chromium data (cohort 1)

Gene Set Enrichment Analysis (GSEA)

The log2-fold change of differentially expressed genes (with high counts, i.e., “baseMean” > 100) from DESeq2 was used to define the ranked gene list used for GSEA. We tested three signatures (listed in Table S2): (1) RESPONSE TO TYPE I INTERFERON (GO:0034340), DEFENSE RESPONSE TO VIRUS (GO:0051607), and cytotoxicity. Gene lists (1) and (2) were obtained from the Molecular Signatures Database (MSigDB) (Subramanian et al., 2005), and for the cytotoxicity signature we used 17 cytotoxicity - associated genes taken from T_CELL_MEDIATED_CYTOTOXICITY (GO:0001913) and (Zhang et al., 2020). GSEA was performed with the R package “fgsea” v. 1.16.0 with 1000 permutations for statistical testing.

ScRNA-seq data analysis of Rhapsody data (cohort 2)

Detection of SARS-CoV-2-specific IgG and IgA antibodies

Detection of IgG and IgA to the S1 domain of the SARS-CoV-2 spike (S) protein were assessed by anti-SARS-CoV-2 S1 IgG ELISAs (Euroimmun AG, Germany), as described elsewhere (Schlickeiser et al., 2020). Serum samples were tested at a 1:101 dilution and optical density (OD) ratios were calculated by dividing the OD at 450 nm by the OD of a calibrator sample tested within each run. Therefore, the calculated OD ratios can be used as a relative measure for the concentration of IgA and IgG antibodies in the tested sample. For IgG and IgA, OD ratios of above 1.1 were considered to be reactive.

Ex vivo functional analyses of T cells